



RECEIVED

SEP 21 2001

TECH CENTER 1600/2900

## SEQUENCE LISTING

<110> FAIRLIE, DAVID  
 MAXWELL, STEPHEN  
 FINCH, ANGELA MONIQUE  
 WONG, ALLAN

<120> CYCLIC ANAGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PR  
 OTEIN-COUPLED RECEPTORS

<130> 10648-0001-0PCT

<140> 09/446,109

<141> 2000-04-21

<150> PCT/AU98/00490

<151> 1998-06-25

<150> AU P07550

<151> 1997-06-25

<160> 24

<170> PatentIn version 3.1

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 1

Ile Ser His Lys Asp Met Gln Leu Gly Arg  
 1 5 10

<210> 2

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 2

Tyr Ser Phe Lys Asp Met Gln Leu Gly Arg  
 1 5 10

<210> 3  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> misc\_feature  
<222> (9)..(9)  
<223> Xaa is D-Ala

<400> 3

Tyr Ser Phe Lys Asp Met Pro Leu Xaa Arg  
1 5 10

<210> 4  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> misc\_feature  
<222> (9)..(9)  
<223> Xaa is D-Ala

<400> 4

Tyr Ser Phe Lys Pro Met Pro Leu Xaa Arg  
1 5 10

<210> 5  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> misc\_feature  
<222> (11)..(11)

<223> MOD\_RES: Acp

<220>

<221> misc\_feature

<222> (20)..(20)

<223> Xaa is D-Ala

RECEIVED

SEP 21 2001

TECH CENTER 1600/2300

<400> 5

Arg	Ala	Ala	Arg	Ile	Ser	Leu	Gly	Pro	Arg	Xaa	Tyr	Ser	Phe	Lys	Pro
1				5					10					15	

Met	Pro	Leu	Xaa	Arg
			20	

<210> 6

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> misc\_feature

<222> (10)..(10)

<223> MOD\_RES: Acp

<220>

<221> misc\_feature

<222> (19)..(19)

<223> Xaa is D-Ala

<400> 6

Lys	Tyr	Lys	His	Ser	Val	Val	Lys	Lys	Xaa	Tyr	Ser	Phe	Lys	Pro	Met
1				5					10					15	

Pro	Leu	Xaa	Arg
			20

<210> 7

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> METHYLATION

<220>

<221> misc\_feature

<222> (4)..(4)

<223> Xaa is D-cyclohexylalanine

<400> 7

Phe Lys Pro Xaa Trp Arg

1 5

<210> 8

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> METHYLATION

<220>

<221> misc\_feature

<222> (4)..(4)

<223> Xaa is D-cyclohexylalanine

<220>

<221> MOD\_RES

<222> (6)..(6)

<223> residue is substituted with (CO)NH2

<400> 8

Phe Lys Pro Xaa Trp Arg

1

5

<210> 9  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> METHYLATION

<220>  
 <221> misc\_feature  
 <222> (4)..(4)  
 <223> Xaa is D-cylcohexylalanine

<400> 9

Phe Lys Pro Xaa Trp Arg  
 1 5

<210> 10  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> METHYLATION

<400> 10

Phe Lys Pro Leu Trp Arg  
 1 5

<210> 11  
 <211> 6  
 <212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> SITE

<222> (2)..(6)

<223> cyclic portion

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> ACETYLTATION

<220>

<221> misc\_feature

<222> (4)..(4)

<223> Xaa is D-cylcohexylalanine

<400> 11

Phe Lys Pro Xaa Trp Arg

1 5

<210> 12

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> ACETYLTATION

<220>

<221> misc\_feature

<222> (2)..(2)

<223> Orn

<220>

<221> misc\_feature

<222> (4)..(4)

<223> D-cyclohexylalanine

<220>

<221> SITE

<222> (2)..(6)

<223> cyclic portion

<400> 12

Phe Xaa Pro Xaa Trp Arg

1 5

<210> 13

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> SITE

<222> (1)..(2)

<223> between residues 1 and 2: (CH<sub>2</sub>)-NH<sub>2</sub>

<220>

<221> misc\_feature

<222> (3)..(3)

<223> Xaa is D-cyclohexylalanine

<220>

<221> SITE

<222> (1)..(5)

<223> cyclic portion is from residue 5 and the (CH<sub>2</sub>) NH<sub>2</sub> moiety present  
between residues 1 and 2

<400> 13

Phe Pro Xaa Trp Arg

1 5

<210> 14

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> misc\_feature

<222> (3)..(3)

<223> Xaa is D-cyclohexylalanine

<220>

<221> misc\_feature

<222> (1)..(2)

<223> between residues 1 and 2: (CH<sub>2</sub>)-NH<sub>2</sub>

<220>

<221> SITE

<222> (1)..(5)

<223> cyclic portion is from residue 5 and the (CH<sub>2</sub>)-NH<sub>2</sub> moiety  
between  
residues 1 and 2

<400> 14

Phe Pro Xaa Trp Arg

1

5

<210> 15

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<220>

<221> misc\_feature

<222> (1)..(2)

<223> between residues 1 and 2: (CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub>

<220>

<221> misc\_feature

<222> (3)..(3)

<223> Xaa is D-cyclohexylalanine

<220>

<221> SITE  
<222> (1)..(5)  
<223> cyclic portion is from residue 5 and the (CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub> moiety  
between  
n residues 1 and 2

<400> 15

Phe Pro Xaa Trp Arg  
1 5

<210> 16  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> misc\_feature  
<222> (1)..(2)  
<223> between residues 1 and 2: (CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub>

<220>  
<221> misc\_feature  
<222> (3)..(3)  
<223> Xaa is D-cyclohexylalanine

<220>  
<221> SITE  
<222> (1)..(5)  
<223> cyclic portion is from residue 5 and the (CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub> moiety  
between  
n residues 1 and 2

<400> 16

Phe Pro Xaa Trp Arg  
1 5

<210> 17  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> ACETYLATION

<220>  
 <221> misc\_feature  
 <222> (2)..(2)  
 <223> Xaa is Orn

<220>  
 <221> misc\_feature  
 <222> (4)..(4)  
 <223> Xaa is D-cyclohexylalanine

<220>  
 <221> misc\_feature  
 <222> (2)..(6)  
 <223> cyclic portion

<400> 17

Phe Xaa Pro Xaa Trp Arg  
 1 5

<210> 18  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> ACETYLATION

<220>  
 <221> misc\_feature  
 <222> (2)..(2)  
 <223> Orn

<220>  
 <221> misc\_feature  
 <222> (4)..(4)  
 <223> Xaa is D-cyclohexylalanine

<220>  
 <221> SITE  
 <222> (2)..(6)  
 <223> cyclic portion

<400> 18

Phe Xaa Pro Xaa Trp Arg  
 1 5

<210> 19  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> misc\_feature  
 <222> (4)..(4)  
 <223> Xaa is D-cyclohexylalanine

<220>  
 <221> SITE  
 <222> (1)..(6)  
 <223> cyclic portion

<400> 19

Phe Trp Pro Xaa Trp Arg  
 1 5

<210> 20  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION

<220>  
<221> misc\_feature  
<222> (4)..(4)  
<223> Xaa is D-cyclohexylalanine

<220>  
<221> SITE  
<222> (2)..(6)  
<223> cyclic portion

<400> 20

Phe Lys Met Xaa Trp Arg  
1 5

<210> 21  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION

<220>  
<221> misc\_feature  
<222> (4)..(4)  
<223> Xaa is D-cyclohexylalanine

<220>  
<221> SITE  
<222> (2)..(6)  
<223> cyclic portion

<400> 21

Phe Lys Lys Xaa Trp Arg  
1 5

<210> 22  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> ACETYLATION

<220>  
<221> SITE  
<222> (2)..(2)  
<223> Xaa is (CH<sub>2</sub>)-NH<sub>2</sub>

<220>  
<221> misc\_feature  
<222> (3)..(3)  
<223> Xaa is D-cyclohexylalanine

<220>  
<221> SITE  
<222> (1)..(5)  
<223> cyclic portion is from residue 5 and the (CH<sub>2</sub>)-NH<sub>2</sub> moiety  
between  
residues 1 and 2

<400> 22

Phe Pro Xaa Trp Arg  
1 5

<210> 23  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> ACETYLTATION

<220>  
 <221> SITE  
 <222> (1)..(2)  
 <223> between residues 1 and 2: (CH<sub>2</sub>)-NH<sub>2</sub>

<220>  
 <221> misc\_feature  
 <222> (3)..(3)  
 <223> residue is D-cyclohexylalanine

<220>  
 <221> SITE  
 <222> (1)..(5)  
 <223> cyclic portion is from residue 5 and the (CH<sub>2</sub>)<sub>2</sub>-NH<sub>2</sub> moiety  
 between  
 n residues 1 and 2

<400> 23

Phe Pro Xaa Trp Arg  
 1 5

<210> 24  
 <211> 7  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> synthetic peptide

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> ACETYLTATION

<220>  
 <221> misc\_feature  
 <222> (3)..(3)  
 <223> Orn

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> Xaa is D-cyclohexylalanine

<220>  
<221> SITE  
<222> (3)..(7)  
<223> cyclic portion

<400> 24

Lys Phe Xaa Pro Xaa Trp Arg  
1 5